Company Overview
About Poplar Therapeutics
Poplar Therapeutics (formerly Phylaxis Bioscience) raised $95 million in less than 60 days — $50 million in Series A financing in January 2026 from SR One, Vida Ventures, RA Capital, and Janus Henderson, extended by $45 million in March 2026 — reflecting exceptional investor conviction in its PHB-050 anti-IgE program. PHB-050 uses a triple-action anti-IgE mechanism designed to exceed the performance of existing anti-IgE drugs: simultaneously blocking mast cell IgE binding, reducing circulating free IgE, and inhibiting IgE production by B cells. Phase 1 data is expected in the second half of 2026.
Business Model & Competitive Advantage
IgE is the antibody isotype that drives allergic responses: food allergies, asthma, atopic dermatitis, and eosinophilic disorders are all IgE-mediated conditions. Xolair (omalizumab, $3B+ annually) is the only approved anti-IgE antibody, blocking free IgE from binding to mast cells but without reducing total IgE production. Dupixent addresses atopic conditions through a different mechanism. PHB-050's triple mechanism — acting at three points in the IgE pathway simultaneously — may achieve more complete IgE suppression than Xolair, enabling treatment of patients with higher IgE levels that Xolair cannot adequately control.
Competitive Landscape 2025–2026
The $95 million in 60 days without clinical data is a strong signal of institutional conviction in the preclinical pharmacology: SR One, Vida, and RA Capital are among the most scientifically rigorous biotech investors who require compelling preclinical data before committing capital at this scale.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Poplar Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Poplar Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Poplar Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Poplar Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Poplar Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →